Tarlatamab + YL201 for Lung Cancer

((DeLLphi-310) Trial)

This trial tests the safety and tolerability of two drugs, tarlatamab and YL201, for treating extensive-stage small cell lung cancer (ES-SCLC). The goal is to identify the best dose combinations for these drugs, sometimes adding a third drug to boost the immune system's ability to fight cancer. Suitable candidates have ES-SCLC that has returned or worsened after standard treatments and have at least one measurable tumor. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that tarlatamab, when combined with YL201, has been studied to assess its safety and patient tolerance. Early results focus on patient response to the treatment and any side effects.

Interest also exists in how this combination interacts with anti-PD-L1 drugs like atezolizumab or durvalumab, which enhance the immune system's ability to fight cancer. Previous studies found that combining tarlatamab with a PD-L1 inhibitor was generally safe, with patients tolerating the treatment well.

Researchers are excited about Tarlatamab and YL201 for lung cancer because they offer a novel approach compared to traditional treatments like chemotherapy and targeted therapies. Tarlatamab is designed to target specific proteins on cancer cells, potentially enhancing the immune system's ability to fight tumors, while YL201 is being explored for its effectiveness when combined with this targeted approach. Additionally, the study is investigating how these drugs work with an anti-PD-L1 like atezolizumab or durvalumab, which are already known to boost immune response against cancer. This combination could provide a powerful new option for patients, especially if the drugs prove effective at lower doses with manageable side effects.

Research shows that tarlatamab holds promise for treating lung cancer. Studies have found that tarlatamab can lower the risk of death by 40% and increase the average survival time by over five months compared to other treatments. When combined with chemotherapy or immunotherapy, tarlatamab has successfully shrunk tumors in 71% of patients. This trial studies the combination of tarlatamab with YL201, and early results are encouraging. Additionally, some participants will receive a combination that includes tarlatamab, YL201, and an immune-boosting drug like atezolizumab or durvalumab, which may enhance the treatment's effectiveness.¹³⁶⁷⁸